The Department of Justice has issued a strong warning in recent months to those in the pharmaceutical and healthcare industries: find a way to deter fraud and other corporate corruption, or face hefty consequences.
The opening declaration came from Assistant Attorney General Lanny Breuer in a speech last November, when he pointedly said: “Pharmaceutical companies must ensure that they are dealing honestly and fairly with patients, healthcare providers, private insurers, and government programs.” If they don’t, he advised, the Justice Department will be “vigilant” in holding companies and individuals who break the law accountable, particularly for violations under the Foreign Corrupt Practices Act.
